Literature DB >> 1349082

Thalidomide for systemic lupus erythematosus.

D F Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349082     DOI： 10.1016/0140-6736(92)90580-v

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Guideline for the clinical use and dispensing of thalidomide.

Authors:  R J Powell; J M Gardner-Medwin
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

2.  Thalidomide--the way forward.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

3.  Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs.

Authors:  Colleen Goosen; Timothy J Laing; Plessis Jeanetta du; Theunis C Goosen; Gordon L Flynn
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 4.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

5.  A case of refractory Henoch-Schönlein purpura treated with thalidomide.

Authors:  Soo Jeong Choi; Sung Kyu Park; Wan Sik Uhm; Dae Sik Hong; Hee Sook Park; Young Lip Park; Kye Won Kwon
Journal:  Korean J Intern Med       Date:  2002-12       Impact factor: 2.884
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.